Jill Marie Broadfoot
CIK 1305178 · Chief Financial Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$725.9K
Companies
7
Total Filings
42
Lifetime Open-Market Net
$85.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TLPH | Director | 13,647 | $1.35 | $18.4K | $0 | 3 | 2026-06-24 |
| ATYR | Chief Financial Officer | 38,854 | $0.48 | $18.8K | -$1.5K | 1 | 2026-02-04 |
| LIFE | Chief Financial Officer | 35,104 | $19.62 | $688.7K | $86.0K | 21 | 2026-01-09 |
| CUE | Director | — | $29.39 | — | $0 | 2 | 2026-01-06 |
| TALPHERA, INC. (ACRX) Delisted | Director | 2,106 | $0.86 | $1.8K | $0 | 3 | 2023-12-13 |
| OTONOMY, INC. (OTIC) Delisted | Director | — | $0.08 | — | $0 | 2 | 2022-06-23 |
| Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Sr Vice President, CFO, Sec | 20,807 | — | — | $961 | 10 | 2013-04-03 |
Recent Filings · Page 5 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-01-31 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Tax (F) | −599 | -$3.7K | EDGAR |
| 2007-01-08 | Fresh Tracks Therapeutics, Inc. (VICL) Delisted | Mixed | +10,000 | $100 | EDGAR |
Showing 41–42 of 42
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.